BeiGene is again attempting reimbursement for its immunotherapy, ‘Tevimbra (tislelizumab)’ in Korea.

According to industry sources, BeiGene Korea recently submitted an application for the reimbursement of its Tevimbra (tiselizumab) and is waiting for the Health Insurance Review and Assessment Service's Cancer Disease Review Committee’s deliberation.

Tevimbra had previously received the ‘reimbursement standards not set' decision by the CDDC in March. Therefore, the industry’s eyes are on whether the company’s second attempt for Tevimbra's reimbursement will be successful.

Tevimbra (tiselizumab), which was approved in Korea last November, is an immuno-oncology drug in